Month: February 2018

Andarix Pharmaceuticals to Present at Regulatory Pathways Summit Conference

Feb 12, 2018

—

by

cadams

in Article

lung cancer, orphan drug, personalized medicine, radiotherapy, sclc, small cell lung cancer, targeted therapy

Andarix Pharmaceuticals, a clinical stage company, developing a targeted peptide therapy for small cell lung cancer announced that its Chief Executive Officer, Chris Adams, will present at the Innovative Regulatory Pathways Summit in Washington, DC. January 29-30, 2018.
Andarix Pharmaceuticals to Present Lung Cancer Clinical Trial Results at international lung cancer meeting

Feb 9, 2018

—

by

cadams

in Article

conference, lung cancer, personalized medicine, sclc, small cell lung cancer, targeted therapy

Andarix Pharmaceuticals, a leader in the discovery and development of targeted peptide therapy for cancer announced today that it will present the results of its latest clinical trial in lung cancer patients. The trial focused on the administration of Tozaride, the company’s lead candidate in neuroendocrine lung cancer patients. The data will be presented at…